Press Room
ADAP Advocacy issued the following press releases:
ADAP Advocacy Submits Public Comment on 340B Rebate Model
A 340B Rebate Model is Desperately Needed, Will Restore an Important Measure of Integrity to a Program That Has Lost Its Way
WASHINGTON, D.C. (April 22, 2026) – ADAP Advocacy submitted public comment to the Health Resources and Services Administration (HRSA) in response to the agency’s Request for Information (RFI) on its proposed rebate model for the 340B Drug Pricing Program. The 340B rebate model, which is supported by patient advocacy groups and opposed by 340B profit-driven special-interest groups, would broaden the transparency mechanisms inherent in the proposal to more fully encompass patients, states, researchers, and others.
ADAP Advocacy Applauds Ruling by the U.S. Court of Appeals for the Fourth Circuit on the 340B Drug Pricing Program
Appeals Court’s Decision Puts Patients First by Siding with Accountability
WASHINGTON, D.C. (April 15, 2026) – ADAP Advocacy praises the decision by the U.S. Court of Appeals for the Fourth Circuit, which reversed the District Court’s denial of a preliminary injunction. This injunction was sought by pharmaceutical companies — Novartis, Allergan, AstraZeneca, and PhRMA — to contest Maryland’s H.B. 1056. The law sanctions unlimited growth in the 340B Drug Pricing Program without guardrails for accountability and transparency to prevent waste, fraud, and abuse. ADAP Advocacy had opposed the bill before it became law.
ADAP Advocacy Condemns Proposed Funding Cuts to HIV Programs
Trump Administration’s Proposed 2027 Budget for the U.S. Departments of Health & Human Services and Housing & Urban Development is a Direct Threat to People Living with HIV/AIDS
WASHINGTON, D.C. (April 9, 2026) – ADAP Advocacy condemns in the strongest possible terms the proposed Fiscal Year 2027 Budget submitted to Congress by the Trump Administration. The budget blueprint, while likely dead upon arrival, sends a clear message that the federal government is no longer committed to “give me your tired, your poor” for the nation’s healthcare system, regardless of their immigration status. Over $15.8 billion, or approximately 12%, would be stripped from the U.S. Department of Health & Human Services (HHS), with HIV-related programming being hard hit.
ADAP Advocacy Names 2026 Leadership Awards Honorees at SYNC
“William E. Arnold” ADAP Champion Award Presented to Brian Hujdich
ADAP Lifetime Achievement Award Presented to Wanda Brendle-Moss, RN
WASHINGTON, D.C. (March 19, 2026) - ADAP Advocacy announced its 2026 ADAP Leadership Awards honorees, who embody dedication to improving access to care and treatment for people living with HIV/AIDS. The awards were presented at the SYNChronicity 2026 (#SYNC2026) Annual National Conference for HIV, HCV, STIs, Drug User Health, and LGBTQ Health, after a 7-year pause on the awards.
ADAP Advocacy to Convene 340B Patient Advisory Committee at SYNC
Meeting to be Held as Track Session: “Too Big To Fail: What’s Next for the Federal Drug Pricing Program?”
WASHINGTON, D.C. (March 16, 2026) - ADAP Advocacy, today, announced that the SYNChronicity 2026 (#SYNC2026) Annual National Conference for HIV, HCV, STIs, Drug User Health, and LGBTQ Health would serve as the platform for the next convening of its 340B Patient Advisory Committee. The meeting is slated as a conference track session, featuring Dr. Rory Martin from IQVIA, designed to showcase the patient-centric committee’s deliberations.
ADAP Advocacy & Legacy Health Endowment Publish 340B White Paper
REBATE VS. REVENUE: The Accountability Crisis Threatening the 340B Program
WASHINGTON, D.C. (March 6, 2026) - ADAP Advocacy, today, in partnership with the California-based Legacy Health Endowment, released a thought-provoking white paper focusing on what’s at stake if the federal government fails to reform the 340B Drug Pricing Program, which is now the second largest federal prescription drug program in the United States, behind Medicare Part D. It reassesses the 340B framework through the patient experience, calling for improved oversight and accountability. The white paper, “REBATE VS. REVENUE: The Accountability Crisis Threatening the 340B Program,” makes the case for the new 340B rebate model, highlighting the AIDS Drug Assistance Program as the Gold Standard among covered entities, which already largely operates under this model.
Joint Statement on the Proposed Changes to Florida’s AIDS Drug Assistance Program
ADAP Advocacy and HealthHIV Conjoin Patient and Provider Concerns Threatening the Well-Being of Floridians Living with HIV/AIDS
WASHINGTON, D.C. (March 3, 2026) - ADAP Advocacy and HealthHIV issued the following joint statement in response to the proposed changes to services for People Living with HIV/AIDS (PLWHA) as set forth in the Notice of Proposed Rule (NPR) #30517381, promulgated by the Florida Department of Health (DOH). ADAP Advocacy and HealthHIV have not previously submitted joint public comments; however, the magnitude and consequences of the proposed changes compel a unified response. The proposed changes to Florida Rules 64D-4.002, 64D-4.003, and 64D-4.007 necessitate a joint statement. Written comment was submitted to the state today.
ADAP Advocacy Cautions Proposed Medicare Drug Price Controls Undermine Optimal Patient Care for Patients Living with HIV/AIDS
Centers for Medicare and Medicaid Services' Selection of the Highly Effective, Popular Antiretroviral Biktarvy Opens the Door to Unintended Consequences
WASHINGTON, D.C. (February 24, 2026) - ADAP Advocacy today expressed deep concerns over the Centers for Medicare and Medicaid Services' (CMS) decision to select Biktarvy® (bictegravir, emtricitabine & tenofovir alafenamide), a highly effective and widely used HIV antiretroviral medication, as one of the 15 prescription drugs targeted for government price control under the Medicare Drug Price Negotiation Program for the Initial Price Applicability Year (IPAY) 2028. The decision could threaten the delicate service-delivery system for a health condition long rooted in exceptionalism—the idea that HIV/AIDS requires a response beyond "normal" health interventions.
ADAP Advocacy Rescinds Three-Year Florida Travel Advisory
Ongoing Threats to Accessing Care and Treatment Facing Floridians Living with HIV/AIDS Warrants New Advocacy Strategy
WASHINGTON, D.C. - ADAP Advocacy today announced it has rescinded its travel advisory for people living with HIV/AIDS, which was issued in May 2023. The three-year-old travel advisory had applied to ADAP Advocacy board members, staff, consultants, and scholarship-funded patient advocates, and had also suspended hosting any patient advocacy events in Florida.
ADAP Advocacy is an Organizational Partner of SYNC 2026
National Conference to be held March 18th-20th in Arlington, VA
WASHINGTON, D.C. - ADAP Advocacy today announced it is a proud organizational partner of the SYNChronicity 2026 (#SYNC2026) Annual National Conference for HIV, HCV, STIs, Drug User Health, and LGBTQ Health, to be held March 18th-20th in Arlington, Virginia.
ADAP Advocacy Urges Congress to Reject 340B Special Carveouts
Improving Patient Access and Affordability Depends on the Universal Implementation of the 340B Drug Pricing Program Rebate Model
WASHINGTON, D.C. - ADAP Advocacy cautions against "special" carveouts for Federally Qualified Health Centers (FQHCs), or any other covered entities, participating in the federal 340B Drug Pricing Program. The Trump Administration has joined a growing chorus calling for long-overdue reforms to the 340B Program, most notably by proposing a rebate model to replace the current upfront payments that drug manufacturers make to covered entities, which have led to increasing waste, fraud, and abuse.
ADAP Advocacy Urges Congress to Rein in Greedy American Health Insurance Companies
Major health insurers continue to rake in profits at the expense of patients, reporting revenue growth of 7.8% or greater, while patients struggle to afford ACA marketplace premium increases averaging 21.7% of Silver-level plans
WASHINGTON, D.C. - ADAP Advocacy insists that patients’ health is significantly more important than corporate profits for American health insurance companies. This message, however, seems not to have reached the ears of the four major health insurance companies, whose CEOs today testified before Congress before the House Committee on Energy and Commerce and the House Committee on Ways and Means.